Device Trial Radar · NCT06921707
Pilot Trial for WounDx Clinical Decision Support Tool
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Duke University; University of Alabama at Birmingham; Brooke Army Medical Center; Grady Memorial Hospital; Indiana University Health; Uniformed Services University of the Health Sciences; Emory University
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research is to evaluate the overall use of the WounDx medical device in a clinical setting, such as a hospital. The WounDx device is experimental and not yet approved by the United States Food and Drug Administration (FDA). WounDx uses information about a patient's wound to generate a report that a surgeon may use to help determine when to close or not close the wound. The final decision to close the wound remains with the surgeon. The results from this pilot trial will inform a larger pivotal trial.
Conditions
- Wounds
- Wounds and Injuries
- Extremity Injury
- Traumatic Wounds and Injuries
- Amputation, Traumatic/Surgery
- Amputation, Wound
- Open Fracture Wounds
Interventions
Clinical Decision Support ToolDevice
WounDx is a clinical decision support tool that combines an immunoassay of six inflammatory biomarkers measured in wound effluent with wound characteristics to estimate the probability of successful wound closure. A probability of 0.85 or greater indicates a recommendation to close the wound at the next wound care procedure occurring 48-96 hours after the previous procedure. WounDx is applicable up to 21 days post-injury and augments the clinicians' judgment; the final closure decision remains with the clinician.
Standard of Care (SOC)Procedure
The standard of care consists of negative pressure wound therapy and serial wound care procedures, including wound irrigation, surgical debridement, operative washout, and NPWT dressing changes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Meeting Each Pilot Trial Operational Endpoint, by SiteTime frame: From enrollment through follow-up, 30-60 days after wound closure or 21 days post-injury, whichever occurs first (up to approximately 3 months)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama - Birmingham Hospital
Birmingham, Alabama · Recruiting
Emory University / Grady Memorial Hospital
Atlanta, Georgia · Recruiting
Indiana University Health University Hospital
Indianapolis, Indiana · Recruiting
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.